RXi Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RXII)

$0.63 0.06 (10.53 %)
(As of 12/11/2017 09:54 AM ET)
Previous Close$0.57
Today's Range$0.57 - $0.63
52-Week Range$0.32 - $1.88
Volume141,400 shs
Average Volume589,579 shs
Market Capitalization$14.86 million
P/E RatioN/A
Dividend YieldN/A
Beta1.38

About RXi Pharmaceuticals (NASDAQ:RXII)

RXi Pharmaceuticals logoRXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company's development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.

Receive RXII News and Ratings via Email

Sign-up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RXII
CUSIPN/A
Phone508-767-3861

Debt

Debt-to-Equity RatioN/A
Current Ratio2.20%
Quick Ratio2.20%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$20,000.00
Price / Sales746.55
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book1.13

Profitability

Trailing EPS($1.09)
Net Income$-8,990,000.00
Net MarginsN/A
Return on Equity-157.22%
Return on Assets-102.29%

Miscellaneous

Employees15
Outstanding Shares23,700,000

RXi Pharmaceuticals (NASDAQ:RXII) Frequently Asked Questions

What is RXi Pharmaceuticals' stock symbol?

RXi Pharmaceuticals trades on the NASDAQ under the ticker symbol "RXII."

How were RXi Pharmaceuticals' earnings last quarter?

RXi Pharmaceuticals Corporation (NASDAQ:RXII) released its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.11). During the same period in the previous year, the business posted ($0.34) EPS. View RXi Pharmaceuticals' Earnings History.

When will RXi Pharmaceuticals make its next earnings announcement?

RXi Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March, 29th 2018. View Earnings Estimates for RXi Pharmaceuticals.

Who are some of RXi Pharmaceuticals' key competitors?

Who are RXi Pharmaceuticals' key executives?

RXi Pharmaceuticals' management team includes the folowing people:

  • Robert J. Bitterman, Independence Chairman of the Board (Age 65)
  • Geert Cauwenbergh Ph.D., President, Chief Executive Officer, acting Chief Financial Officer, Director (Age 63)
  • Gerrit Dispersyn, Chief Development Officer
  • Keith L. Brownlie CPA, Independent Director (Age 64)
  • H. Paul Dorman, Independent Director (Age 79)
  • Jonathan E Freeman Ph.D., Independent Director
  • Curtis A. Lockshin Ph.D., Independent Director (Age 56)

How do I buy RXi Pharmaceuticals stock?

Shares of RXi Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RXi Pharmaceuticals' stock price today?

One share of RXi Pharmaceuticals stock can currently be purchased for approximately $0.63.

How big of a company is RXi Pharmaceuticals?

RXi Pharmaceuticals has a market capitalization of $14.86 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-8,990,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. RXi Pharmaceuticals employs 15 workers across the globe.

How can I contact RXi Pharmaceuticals?

RXi Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The biotechnology company can be reached via phone at 508-767-3861 or via email at [email protected]


MarketBeat Community Rating for RXi Pharmaceuticals (RXII)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  73 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  152
MarketBeat's community ratings are surveys of what our community members think about RXi Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

RXi Pharmaceuticals (NASDAQ:RXII) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/ABuyBuyBuy
Consensus Rating Score: N/A3.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.71$2.61$2.61$2.61
Price Target Upside: 6.87% upside62.81% upside62.81% upside62.81% upside

RXi Pharmaceuticals (NASDAQ:RXII) Consensus Price Target History

Price Target History for RXi Pharmaceuticals (NASDAQ:RXII)

RXi Pharmaceuticals (NASDAQ:RXII) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2016S&P Equity ResearchLower Price Target$2.35 -> $1.71N/AView Rating Details
6/7/2016HC WainwrightInitiated CoverageBuy$3.50N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

RXi Pharmaceuticals (NASDAQ:RXII) Earnings History and Estimates Chart

Earnings by Quarter for RXi Pharmaceuticals (NASDAQ:RXII)

RXi Pharmaceuticals (NASDAQ RXII) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2018        
11/8/2017Q3 2017($0.11)($0.11)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.11)($0.11)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.20)($0.12)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.23)($0.60)ViewN/AView Earnings Details
11/10/2016Q316($0.34)($0.34)ViewN/AView Earnings Details
8/11/2016Q216($0.36)($0.34)$0.01 millionViewListenView Earnings Details
5/13/2016Q116($0.45)($0.34)$34.00 million$10.00 millionViewListenView Earnings Details
3/30/2016Q415($0.05)($0.04)ViewListenView Earnings Details
11/12/2015Q315($0.04)($0.04)ViewListenView Earnings Details
8/12/2015Q215($0.09)($0.05)$0.02 millionViewListenView Earnings Details
5/13/2015Q115($0.10)($0.13)$0.02 million$0.03 millionViewListenView Earnings Details
3/30/2015Q414($0.14)($0.13)$0.02 million$0.01 millionViewN/AView Earnings Details
11/13/2014Q314($0.22)($0.17)$0.02 millionViewN/AView Earnings Details
8/14/2014Q214($0.25)($0.23)$0.01 millionViewN/AView Earnings Details
5/14/2014Q114($0.31)($0.32)$0.08 million$0.03 millionViewN/AView Earnings Details
3/28/2014($0.31)$0.84ViewN/AView Earnings Details
11/14/2012Q312($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

RXi Pharmaceuticals (NASDAQ:RXII) Earnings Estimates

2017 EPS Consensus Estimate: ($0.74)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.20)($0.20)($0.20)
Q2 20171($0.20)($0.20)($0.20)
Q3 20171($0.17)($0.17)($0.17)
Q4 20171($0.17)($0.17)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for RXi Pharmaceuticals (NASDAQ:RXII)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

RXi Pharmaceuticals (NASDAQ RXII) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.71%
Institutional Ownership Percentage: 1.50%
Insider Trades by Quarter for RXi Pharmaceuticals (NASDAQ:RXII)
Insider Trades by Quarter for RXi Pharmaceuticals (NASDAQ:RXII)

RXi Pharmaceuticals (NASDAQ RXII) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Geert CauwenberghCEOBuy10,000$0.45$4,500.00View SEC Filing  
9/7/2017Alexey EliseevInsiderSell176,800$0.54$95,472.00View SEC Filing  
9/1/2017Alexey EliseevInsiderSell23,200$0.57$13,224.00View SEC Filing  
8/24/2017Geert CauwenberghCEOBuy10,000$0.55$5,500.00View SEC Filing  
6/23/2017Gerrit DispersynInsiderBuy3,500$0.62$2,170.00View SEC Filing  
6/22/2017Geert CauwenberghCEOBuy10,000$0.63$6,300.00View SEC Filing  
4/26/2017Geert CauwenberghCEOBuy10,000$0.65$6,500.00View SEC Filing  
3/17/2017Geert CauwenberghCEOBuy10,000$0.77$7,700.00View SEC Filing  
2/17/2017Geert CauwenberghCEOBuy10,000$0.69$6,900.00View SEC Filing  
2/8/2017Geert CauwenberghCEOBuy10,000$0.69$6,900.00View SEC Filing  
1/25/2017Geert CauwenberghCEOBuy10,000$0.70$7,000.00View SEC Filing  
1/19/2017Geert CauwenberghCEOBuy10,000$0.69$6,900.00View SEC Filing  
4/2/2015Geert CauwenberghCEOBuy5,000$0.72$3,600.00View SEC Filing  
2/17/2015Geert CauwenberghCEOBuy4,000$1.17$4,680.00View SEC Filing  
2/10/2015Geert CauwenberghCEOBuy2,000$1.24$2,480.00View SEC Filing  
1/22/2015Robert J BittermanDirectorBuy5,000$1.20$6,000.00View SEC Filing  
1/20/2015Geert CauwenberghCEOBuy10,000$1.03$10,300.00View SEC Filing  
12/30/2014Geert CauwenberghCEOBuy2,500$1.59$3,975.00View SEC Filing  
10/13/2014Geert CauwenberghCEOBuy3,000$1.68$5,040.00View SEC Filing  
9/19/2014Geert CauwenberghCEOBuy4,500$2.20$9,900.00View SEC Filing  
9/16/2014Geert CauwenberghCEOBuy5,000$2.08$10,400.00View SEC Filing  
9/15/2014Geert CauwenberghCEOBuy10,000$2.18$21,800.00View SEC Filing  
7/15/2014Geert CauwenberghCEOBuy1,000$2.50$2,500.00View SEC Filing  
7/9/2014Geert CauwenberghCEOBuy1,400$2.57$3,598.00View SEC Filing  
7/2/2014Geert CauwenberghCEOBuy2,000$2.86$5,720.00View SEC Filing  
6/19/2014Geert CauwenberghCEOBuy2,000$2.98$5,960.00View SEC Filing  
6/9/2014Geert CauwenberghCEOBuy1,000$3.05$3,050.00View SEC Filing  
6/4/2014Geert CauwenberghCEOBuy2,000$2.94$5,880.00View SEC Filing  
10/31/2013Geert CauwenberghCEOBuy1,000$3.17$3,170.00View SEC Filing  
10/23/2013Geert CauwenberghCEOBuy1,000$3.34$3,340.00View SEC Filing  
10/9/2013Geert CauwenberghCEOBuy1,000$3.15$3,150.00View SEC Filing  
8/29/2013Curtis LockshinDirectorBuy1,000$3.70$3,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

RXi Pharmaceuticals (NASDAQ RXII) News Headlines

Source:
DateHeadline
RXII: sd-rxRNA: A Flexible Platform for OncologyRXII: sd-rxRNA: A Flexible Platform for Oncology
finance.yahoo.com - December 7 at 3:20 PM
RXI Pharma (RXII) Announces Research Collaboration with Center for Cancer Immune Therapy at Herlev Hospital - StreetInsider.comRXI Pharma (RXII) Announces Research Collaboration with Center for Cancer Immune Therapy at Herlev Hospital - StreetInsider.com
www.streetinsider.com - December 2 at 7:52 AM
RXi Pharmaceuticals and the Center for Cancer Immune Therapy at Herlev Hospital Announce Research CollaborationRXi Pharmaceuticals and the Center for Cancer Immune Therapy at Herlev Hospital Announce Research Collaboration
finance.yahoo.com - December 1 at 3:20 PM
RXI Pharma (RXII) Reports Reports Positive Results with RXI-231 - StreetInsider.comRXI Pharma (RXII) Reports Reports Positive Results with RXI-231 - StreetInsider.com
www.streetinsider.com - November 30 at 6:48 AM
RXi Pharma: Consumer Testing Shows RXI-231s Potential To Cut Skin PigmentationRXi Pharma: Consumer Testing Shows RXI-231's Potential To Cut Skin Pigmentation
www.nasdaq.com - November 29 at 3:19 PM
RXi Pharmaceuticals Announces Positive Results with RXI-231 in Consumer Testing ProgramRXi Pharmaceuticals Announces Positive Results with RXI-231 in Consumer Testing Program
finance.yahoo.com - November 29 at 3:19 PM
What Are The Drivers Of RXi Pharmaceuticals Corporation’s (RXII) Risks?What Are The Drivers Of RXi Pharmaceuticals Corporation’s (RXII) Risks?
finance.yahoo.com - November 22 at 7:17 AM
Corporate News Blog - RXi Pharma Collaborates with Gustave Roussy, Europes Leading Cancer CentreCorporate News Blog - RXi Pharma Collaborates with Gustave Roussy, Europe's Leading Cancer Centre
finance.yahoo.com - November 15 at 7:54 AM
RXi Pharmaceuticals and Gustave Roussy Announce Research CollaborationRXi Pharmaceuticals and Gustave Roussy Announce Research Collaboration
finance.yahoo.com - November 14 at 7:33 AM
Edited Transcript of RXII earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of RXII earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 12 at 12:33 PM
RXi Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Corporate HighlightsRXi Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - November 9 at 12:50 PM
RXi Pharmaceuticals Corporation to Host Earnings CallRXi Pharmaceuticals Corporation to Host Earnings Call
finance.yahoo.com - November 9 at 12:50 PM
RXi Pharmaceuticals Corporation (RXII) Posts  Earnings ResultsRXi Pharmaceuticals Corporation (RXII) Posts Earnings Results
www.americanbankingnews.com - November 8 at 2:39 PM
RXi Pharmaceuticals Announces Participation in Leading European Healthcare Forums and ConferencesRXi Pharmaceuticals Announces Participation in Leading European Healthcare Forums and Conferences
finance.yahoo.com - November 7 at 9:46 AM
Critical Comparison: RXi Pharmaceuticals Corporation (RXII) and Its CompetitorsCritical Comparison: RXi Pharmaceuticals Corporation (RXII) and Its Competitors
www.americanbankingnews.com - November 3 at 7:53 AM
RXi Pharmaceuticals to Webcast Third Quarter 2017 Financial Results on Wednesday, November 8, 2017RXi Pharmaceuticals to Webcast Third Quarter 2017 Financial Results on Wednesday, November 8, 2017
finance.yahoo.com - November 1 at 8:23 AM
RXi Pharmaceuticals Corporation (RXII) Scheduled to Post Quarterly Earnings on WednesdayRXi Pharmaceuticals Corporation (RXII) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:50 AM
RXi Pharmaceuticals Corporation (RXII) Expected to Post Earnings of -$0.11 Per ShareRXi Pharmaceuticals Corporation (RXII) Expected to Post Earnings of -$0.11 Per Share
www.americanbankingnews.com - October 31 at 5:12 AM
RXi Pharmaceuticals (RXII) Presents At 2017 BIO Investor Forum - SlideshowRXi Pharmaceuticals (RXII) Presents At 2017 BIO Investor Forum - Slideshow
seekingalpha.com - October 20 at 4:47 PM
RXi Pharmaceuticals Corporation (RXII) vs. Immunomedics (IMMU) Head to Head ContrastRXi Pharmaceuticals Corporation (RXII) vs. Immunomedics (IMMU) Head to Head Contrast
www.americanbankingnews.com - October 15 at 8:28 PM
RXi Pharmaceuticals to Present at the 2017 Annual BIO Investor Forum - PR Newswire (press release)RXi Pharmaceuticals to Present at the 2017 Annual BIO Investor Forum - PR Newswire (press release)
www.prnewswire.com - October 12 at 3:21 PM
RXi Pharmaceuticals to Present at the 2017 Annual BIO Investor ForumRXi Pharmaceuticals to Present at the 2017 Annual BIO Investor Forum
finance.yahoo.com - October 11 at 7:23 AM
RXi Pharmaceuticals to Present at the 2017 Annual BIO Investor ForumRXi Pharmaceuticals to Present at the 2017 Annual BIO Investor Forum
finance.yahoo.com - October 11 at 7:23 AM
Streetwise Reports Interviews Executives at Biotech Company with Transformative RNAi Delivery SystemStreetwise Reports Interviews Executives at Biotech Company with Transformative RNAi Delivery System
finance.yahoo.com - October 6 at 8:14 AM
RXi Pharmaceuticals (RXII) Presents At 10th Annual International Partnering Conference BioPharm America - SlideshowRXi Pharmaceuticals (RXII) Presents At 10th Annual International Partnering Conference BioPharm America - Slideshow
seekingalpha.com - September 28 at 8:10 PM
RXi Pharmaceuticals (RXII) Presents At Ladenburg Thalmann 2017 Healthcare Conference - SlideshowRXi Pharmaceuticals (RXII) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 4:32 PM
RXi Pharmaceuticals sd-rxRNA: Better delivery than Amazon! - Yahoo NewsRXi Pharmaceuticals' sd-rxRNA: Better delivery than Amazon! - Yahoo News
finance.yahoo.com - September 26 at 8:42 AM
RXi Pharmaceuticals’ sd-rxRNA: Better delivery than Amazon!RXi Pharmaceuticals’ sd-rxRNA: Better delivery than Amazon!
finance.yahoo.com - September 26 at 8:42 AM
Head to Head Contrast: RXi Pharmaceuticals Corporation (RXII) versus Alnylam Pharmaceuticals (ALNY)Head to Head Contrast: RXi Pharmaceuticals Corporation (RXII) versus Alnylam Pharmaceuticals (ALNY)
www.americanbankingnews.com - September 24 at 10:08 PM
 Analysts Anticipate RXi Pharmaceuticals Corporation (RXII) Will Announce Earnings of -$0.11 Per Share Analysts Anticipate RXi Pharmaceuticals Corporation (RXII) Will Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - September 23 at 2:26 PM
RXi Pharmaceuticals to Present at BioPharm Americas 10th Annual International Partnering ConferenceRXi Pharmaceuticals to Present at BioPharm America's 10th Annual International Partnering Conference
finance.yahoo.com - September 19 at 7:21 AM
RXi Pharmaceuticals to Present at Ladenburg Thalmann Healthcare ConferenceRXi Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
finance.yahoo.com - September 19 at 7:20 AM
Featured Company News - RXi Pharmas Chief Business Officer, Alexey Eliseev, to Leave the CompanyFeatured Company News - RXi Pharma's Chief Business Officer, Alexey Eliseev, to Leave the Company
finance.yahoo.com - September 19 at 7:20 AM
RXI Pharma (RXII) Reports Departure of Dr. Alexey Eliseev as Chief Business OfficerRXI Pharma (RXII) Reports Departure of Dr. Alexey Eliseev as Chief Business Officer
www.streetinsider.com - September 16 at 8:18 AM
RXi Pharmaceuticals Announces the Departure of Dr. Alexey Eliseev as Chief Business OfficerRXi Pharmaceuticals Announces the Departure of Dr. Alexey Eliseev as Chief Business Officer
finance.yahoo.com - September 16 at 8:17 AM
BioAxone BioSciences Awarded NINDS SBIR Funding for the Development of Self-Delivering RNAi (sd-rxRNA®) for the Treatment of Spinal Cord InjuryBioAxone BioSciences Awarded NINDS SBIR Funding for the Development of Self-Delivering RNAi (sd-rxRNA®) for the Treatment of Spinal Cord Injury
finance.yahoo.com - September 15 at 8:31 AM
Insider Selling: RXi Pharmaceuticals Corporation (RXII) Insider Sells 176,800 Shares of StockInsider Selling: RXi Pharmaceuticals Corporation (RXII) Insider Sells 176,800 Shares of Stock
www.americanbankingnews.com - September 7 at 10:24 PM
RXI Pharma (RXII) Reports Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts - StreetInsider.comRXI Pharma (RXII) Reports Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts - StreetInsider.com
www.streetinsider.com - September 7 at 8:39 AM
RXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous WartsRXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts
finance.yahoo.com - September 6 at 7:56 AM
RXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous WartsRXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts
finance.yahoo.com - September 6 at 7:56 AM
RXi Pharmaceuticals Corp (RXII) Insider Alexey Eliseev Sells 23,200 SharesRXi Pharmaceuticals Corp (RXII) Insider Alexey Eliseev Sells 23,200 Shares
www.americanbankingnews.com - September 1 at 10:24 PM
RXi Pharmaceuticals Corporation Selected to Present at the 8th Annual Investing for Cures ForumRXi Pharmaceuticals Corporation Selected to Present at the 8th Annual Investing for Cures Forum
finance.yahoo.com - August 31 at 9:37 AM
 Brokerages Expect RXi Pharmaceuticals Corporation (RXII) to Announce -$0.11 Earnings Per Share Brokerages Expect RXi Pharmaceuticals Corporation (RXII) to Announce -$0.11 Earnings Per Share
www.americanbankingnews.com - August 17 at 8:18 AM
Edited Transcript of RXII earnings conference call or presentation 10-Aug-17 8:30pm GMTEdited Transcript of RXII earnings conference call or presentation 10-Aug-17 8:30pm GMT
finance.yahoo.com - August 12 at 7:34 AM
Investor Network: RXi Pharmaceuticals Corporation to Host Earnings CallInvestor Network: RXi Pharmaceuticals Corporation to Host Earnings Call
finance.yahoo.com - August 11 at 8:16 AM
RXi Pharmaceuticals Corporation (RXII) Announces  Earnings Results, Hits ExpectationsRXi Pharmaceuticals Corporation (RXII) Announces Earnings Results, Hits Expectations
www.americanbankingnews.com - August 10 at 11:29 PM
Financial Comparison: RXi Pharmaceuticals Corporation (NASDAQ:RXII) and Spectrum Pharmaceuticals (SPPI)Financial Comparison: RXi Pharmaceuticals Corporation (NASDAQ:RXII) and Spectrum Pharmaceuticals (SPPI)
www.americanbankingnews.com - August 10 at 2:36 PM
EARNINGS SUMMARY: Details of RXi Pharmaceuticals Corp. Q2 Earnings ReportEARNINGS SUMMARY: Details of RXi Pharmaceuticals Corp. Q2 Earnings Report
www.rttnews.com - August 10 at 7:33 AM
RXi Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Corporate HighlightsRXi Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - August 10 at 7:33 AM
RXi Pharmaceuticals Advances Immuno-Oncology Pipeline by Selecting Two sd-rxRNA Compounds for Preclinical Development and Sourcing cGMP ManufacturingRXi Pharmaceuticals Advances Immuno-Oncology Pipeline by Selecting Two sd-rxRNA Compounds for Preclinical Development and Sourcing cGMP Manufacturing
finance.yahoo.com - August 9 at 7:08 AM

SEC Filings

RXi Pharmaceuticals (NASDAQ:RXII) SEC Filings

DateFilerForm TypeView

Social Media

Financials

RXi Pharmaceuticals (NASDAQ:RXII) Income Statement, Balance Sheet and Cash Flow Statement

Chart

RXi Pharmaceuticals (NASDAQ RXII) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.